Mauritius Becomes First Nation to Reverse Type 2 Diabetes Prevalence Over 34 Years
A landmark 34-year study shows Mauritius cut type 2 diabetes rates from 23% to 20%, proving national prevention programs can turn the tide.
Summary
A repeated cross-sectional study tracking over 36,000 adults in Mauritius from 1987 to 2021 using the gold-standard oral glucose tolerance test found that type 2 diabetes prevalence peaked at 23.3% in 2009 and then declined significantly to 19.9% by 2021. Intermediate hyperglycemia followed the same arc, falling to 15.6%. Crucially, the proportion of undiagnosed diabetics dropped from 67% to 32.5%, suggesting better detection and treatment. This makes Mauritius the first country to demonstrate a sustained, population-level reversal of type 2 diabetes burden using objective diagnostic criteria. The findings show that sustained national prevention and monitoring efforts can meaningfully reduce metabolic disease — a critical message for aging populations worldwide facing surging diabetes rates.
Detailed Summary
Type 2 diabetes is one of the most consequential metabolic diseases of aging, accelerating cardiovascular disease, cognitive decline, kidney failure, and early death. Demonstrating that its population prevalence can actually be reversed — not merely slowed — would represent a historic public health achievement. This study from Mauritius delivers exactly that evidence.
Researchers analyzed data from seven national non-communicable disease surveys conducted in Mauritius between 1987 and 2021, with 36,744 total survey attendances from adults aged 25–74. Each wave used standardized protocols and the oral glucose tolerance test (OGTT), the WHO-recommended gold-standard diagnostic tool, yielding participation rates above 85% throughout. Glycemic status was classified per WHO 2006 criteria.
In 1987, age- and sex-standardized type 2 diabetes prevalence stood at 14.7%. It climbed steadily, peaking at 23.3% in 2009, before declining significantly to 19.9% in 2021. Intermediate hyperglycemia — a precursor state — followed the same trajectory, peaking at 24.9% in 2009 and falling to 15.6% by 2021. Notably, the decline was consistent across both sexes, all age groups, and multiple ethnic groups. The proportion of newly diagnosed diabetics at survey time fell from 67% in 1987 to just 32.5% in 2021, indicating markedly improved diagnosis and treatment penetration.
The implications are significant. Mauritius is the first country to document a genuine, OGTT-confirmed reversal in type 2 diabetes prevalence at the national level — demonstrating that sustained, systematic prevention and monitoring programs can bend the curve on a disease widely assumed to be epidemiologically intractable.
Caveats apply: the summary is based on the abstract only, so details on the specific interventions driving decline and potential confounders (dietary shifts, medication uptake, demographic changes) cannot be fully assessed. Cross-sectional surveys also cannot establish causality.
Key Findings
- Type 2 diabetes prevalence in Mauritius peaked at 23.3% in 2009 then fell significantly to 19.9% by 2021.
- Intermediate hyperglycemia declined from a peak of 24.9% in 2009 to 15.6% in 2021.
- The reversal was consistent across both sexes, all age groups, and multiple ethnicities.
- Undiagnosed diabetes dropped from 67% of all cases in 1987 to just 32.5% in 2021, showing better detection.
- Mauritius is the first country to show a declining diabetes prevalence using WHO-recommended OGTT criteria.
Methodology
Seven repeated cross-sectional national surveys were conducted in Mauritius from 1987 to 2021, enrolling 36,744 adults aged 25–74 with participation rates above 85% in each wave. All participants underwent fasting plasma glucose measurement; those not pregnant or on glucose-lowering medication also completed an oral glucose tolerance test. Glycemic status was classified using WHO 2006 criteria with age- and sex-standardized prevalence estimates.
Study Limitations
The summary is based on the abstract only, as the full paper is not open access; specific details on interventions, dietary changes, medication use, and confounders cannot be assessed. Cross-sectional surveys cannot establish causality between any specific policy or intervention and the observed prevalence decline. Generalizability to other national contexts with different demographic, ethnic, or healthcare infrastructure profiles may be limited.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: